The Artelo plc drug ART27.13 is a synthetic peripherally selective full CB1R (Ki ~11 nM)/CB2R (Ki ~1 nM) agonist undergoing Phase 2 clinical trials in cancer patients with weight loss and anorexia. This evidence concerns the gene CNR1 and cancer.